Skip to content
PoliticalRepoPoliticalRepo

United States · Bill · HR

H.R. 1776 (115th)

Improving Access To Affordable Prescription Drugs Act

referredUnited States· United States Congress· EN

Introduced

29 March 2017

Last action

5 April 2017 · Referred

Status

Referred to the Subcommittee on Health.

Sponsors

Rep. Schakowsky, Janice D. [D-IL-9], Rep. Cummings, Elijah E. [D-MD-7], Rep. DeLauro, Rosa L. [D-CT-3], Sen. Welch, Peter [D-VT], Rep. Grijalva, Raúl M. [D-AZ-7], Rep. Pocan, Mark [D-WI-2], Rep. Conyers, John, Jr. [D-MI-13], Rep. Peterson, Collin C. [D-MN-7], Rep. Shea-Porter, Carol [D-NH-1], Rep. Barragán, Nanette Diaz [D-CA-44], Rep. Ellison, Keith [D-MN-5], Rep. Rush, Bobby L. [D-IL-1], Rep. Pingree, Chellie [D-ME-1], Rep. Nolan, Richard M. [D-MN-8], Rep. Chu, Judy [D-CA-28], Rep. Cohen, Steve [D-TN-9], Rep. McCollum, Betty [D-MN-4], Rep. Jayapal, Pramila [D-WA-7], Rep. DeFazio, Peter A. [D-OR-4], Rep. Ryan, Tim [D-OH-13], Rep. Visclosky, Peter J. [D-IN-1], Del. Norton, Eleanor Holmes [D-DC-At Large], Rep. Khanna, Ro [D-CA-17], Rep. Maloney, Sean Patrick [D-NY-18]

Subjects

Healthcare, Taxation

Source updated

21 January 2026

Healthcare · Taxation

Official sourceDownload fileView documentsShare

Summary

This bill amends provisions of various laws relating to prescription-drug pricing and affordability. Specifically, the bill: expands reporting requirements for drug manufacturers and establishes corresponding civil penalties for noncompliance; adds reporting requirements for certain nonprofit patient-assistance programs; requires the Government Accountability Office (GAO) to report to Congress on the impact of patient-assistance programs on prescription-drug pricing and expenditures; requires the Centers for Medicare & Medicaid Services (CMS) to negotiate prices for certain prescription drugs under the Medicare program; requires the GAO to report to Congress on such negotiations conducted by the CMS; requires the Centers for Medicare and Medicaid Innovation within the CMS to test specified models for negotiating drug prices; establishes reporting requirements, and corresponding civil penalties for noncompliance, for pharmaceutical companies with respect to spikes in prescription-drug prices; establishes an excise tax on prescription drugs subject to price spikes; lessens prescription-drug cost-sharing requirements under qualified health plans, group health plans, and the Medicare program; modifies provisions related to the importation of prescription drugs; requires drug manufacturers to provide drug rebates for drugs dispensed to certain low-income individuals under the Medicare program; establishes a prize fund for new and more effective treatments of bacterial infections; establishes a Center for Clinical Research within the National Institutes of Health; modifies provisions related to drug exclusivity; allows the Federal Trade Commission to initiate enforcement proceedings against parties to an agreement resolving or settling a patent-infringement claim in connection with the sale of a drug product; requires the Food and Drug Administration to establish a database of generic drugs; and modifies other provisions related to generic drugs, prescription-drug advertising, and product hopping.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 29 March 2017

    Introduced

    Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    Source: IntroReferral

  2. 29 March 2017

    Introduced

    Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    Source: IntroReferral

  3. 29 March 2017

    Introduced

    Introduced in House

    Source: IntroReferral

  4. 29 March 2017

    Introduced

    Introduced in House

    Source: IntroReferral

  5. 31 March 2017

    Referred

    Referred to the Subcommittee on Health.

    Source: Committee

  6. 5 April 2017

    Referred

    Referred to the Subcommittee on Health.

    Source: Committee

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in House (text)

View fileDownload file

This file cannot be previewed here. Use View or Download.

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House (text)

    Introduced in House · EN · 29 March 2017

    ViewDownloadOpen at official source

  • Introduced in House (PDF)

    Introduced in House · EN · 29 March 2017

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House

    summary · EN · 29 March 2017

    Open at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

Related records

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.